Article Information
History
- March 8, 2020.
Article Versions
- You are currently viewing Version 1 of this article (March 8, 2020 - 15:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Wioletta Ruta,*,
- Katarzyna Groborza,
- Linlin Zhangb,c,
- Xinyuanyuan Sunb,c,
- Mikolaj Zmudzinskia,
- Rolf Hilgenfeldb,c and
- Marcin Draga,*
- aDepartment of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wyb. Wyspianskiego 27, 50-370 Wroclaw, Poland
- bInstitute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Luebeck, Ratzeburger Allee 160, 23562 Luebeck, Germany
- cGerman Center for Infection Research (DZIF), Hamburg-Luebeck-Borstel-Riems Site, University of Luebeck, 23562 Luebeck, Germany
- ↵*corresponding authors: wioletta.rut{at}pwr.edu.pl, marcin.drag{at}pwr.edu.pl
Posted March 08, 2020.
Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design
